1. Home
  2. NTRA vs CTVA Comparison

NTRA vs CTVA Comparison

Compare NTRA & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$412.42

Market Cap

47.4B

Sector

Health Care

ML Signal

HOLD

Logo Corteva Inc.

CTVA

Corteva Inc.

HOLD

Current Price

$78.49

Market Cap

56.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
CTVA
Founded
2003
1802
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Farming/Seeds/Milling
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
47.4B
56.6B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
NTRA
CTVA
Price
$412.42
$78.49
Analyst Decision
Strong Buy
Buy
Analyst Count
15
16
Target Price
★ $259.07
$84.13
AVG Volume (30 Days)
1.2M
★ 3.3M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
★ 0.91%
EPS Growth
0.65
★ 23.08
EPS
N/A
★ 2.80
Revenue
$210,939,000.00
★ $17,401,000,000.00
Revenue This Year
$18.08
$6.09
Revenue Next Year
$19.65
$3.28
P/E Ratio
★ N/A
$28.38
Revenue Growth
N/A
★ 2.92
52 Week Low
$157.43
$60.54
52 Week High
$412.93
$90.97

Technical Indicators

Market Signals
Indicator
NTRA
CTVA
Relative Strength Index (RSI) 83.65 38.59
Support Level $187.64 $78.56
Resistance Level N/A $81.07
Average True Range (ATR) 13.27 2.43
MACD 5.99 -0.65
Stochastic Oscillator 95.85 11.69

Price Performance

Historical Comparison
NTRA
CTVA

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About CTVA Corteva Inc.

Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in late 2026. The seeds business will be named Vylor, while the crop protection business will retain the Corteva name and be a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.

Share on Social Networks: